Ono Pharmaceutical Announces Reorganization of its US and Europe Operations

Osaka, Japan, February 28, 2025 – Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President: Toichi Takino, “ONO") announced that it has reorganized the operations of its local subsidiaries in the United States and the United Kingdom in order to accelerate the expansion of its global presence.

In line with the reorganization, key functions of ONO PHARMA USA, INC. (Cambridge, Massachusetts, “OPUS”), including US R&D and commercial and medical affairs, and R&D in Europe, are being integrated into Deciphera Pharmaceuticals, LLC (Deciphera) in July 2025. Deciphera has robust and well-developed R&D capabilities and commercial presence in the US and  Europe. This integration will advance efforts to strengthen Deciphera as a business hub for the Ono Group*, responsible for R&D and sales and marketing operations in the US and Europe in other therapeutic areas in addition to existing oncology efforts. Related to these changes, the R&D functions of ONO PHARMA UK LTD. (London, “OPUK”) will cease operations in March 2025.

OPUS will remain as a center for research collaboration and licensing activities, and OPUK will continue to operate as a center for research collaboration activities.

Ono will continue its efforts to become a global specialty pharma company that delivers innovative pharmaceuticals to patients around the world as quickly as possible.

* The Ono Group refers to the umbrella organization that includes Ono Pharmaceutical Co., Ltd. and its subsidiary companies.

About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company dedicated to creating innovative medicines in specific disease areas. Ono Pharma focuses on oncology, immunology, neurology, and specialty research, prioritizing areas with high medical needs for the discovery and development of innovative new treatments. Founded in 1717 in Osaka, the company has facilities in Japan, the UK, the US, South Korea, and Taiwan. In June 2024, Ono Pharma acquired Deciphera Pharmaceuticals Inc., based in Massachusetts, USA, to strengthen its drug pipeline and support global expansion efforts.

For further information visit: https://www.ono-pharma.com/en

Contact:

Ono Pharmaceutical Co., Ltd. 
Corporate Communications 
public_relations@ono-pharma.com